Press Contact: Kirsten Mabry | (617) 495-4157
Tag: Blavatnik Biomedical Accelerator
March 2nd, 2026
Researchers in Andrew Kruse’s lab overcame a key obstacle in using the hormone relaxin as a therapy for heart disease. With support from Harvard’s Blavatnik Biomedical Accelerator, this discovery led to the launch of Tectonic Therapeutic, which is now testing its relaxin-based drug in clinical trials.
September 25th, 2025
10 new technologies tackling urgent challenges from autoimmune disease to cancer win funding from Blavatnik Biomedical Accelerator.
June 16th, 2025
A lab at Harvard T.H. Chan School of Public Health received industry-sponsored research and aims to translate discoveries about a protein that helps regulate metabolism and inflammation into novel therapeutics for obesity, heart disease, and age-related illnesses.
June 12th, 2025
Video on how OTD supports Harvard’s mission to bring innovation out of labs to make a real-world impact.
May 15th, 2025
Investigating the reasons behind the stall in the decline of cardiovascular disease deaths in the U.S. and the new scientific innovations emerging from Harvard labs that aim to improve treatment and drive death rates down.
